Journal Article

DKFZ-2021-00994

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png From Multiplex Serology to Serolomics-A Novel Approach to the Antibody Response against the SARS-CoV-2 Proteome.

Butt, J. A. (First author)DKFZ* ; Murugan, R.DKFZ* ; Hippchen, T. ; Olberg, S. ; van Straaten, M.DKFZ* ; Wardemann, H.DKFZ* ; Stebbins, E.DKFZ* ; Kräusslich, H.-G. ; Bartenschlager, R.DKFZ* ; Brenner, H.DKFZ* ; Laketa, V. ; Schöttker, B.DKFZ* ; Müller, B. ; Merle, U. ; Waterboer, T. (Last author)DKFZ*

2021
MDPI Basel

This record in other databases:

Please use a persistent id in citations: doi:10.3390/v13050749

Abstract: The emerging SARS-CoV-2 pandemic entails an urgent need for specific and sensitive high-throughput serological assays to assess SARS-CoV-2 epidemiology. We, therefore, aimed at developing a fluorescent-bead based SARS-CoV-2 multiplex serology assay for detection of antibody responses to the SARS-CoV-2 proteome. Proteins of the SARS-CoV-2 proteome and protein N of SARS-CoV-1 and common cold Coronaviruses (ccCoVs) were recombinantly expressed in E. coli or HEK293 cells. Assay performance was assessed in a COVID-19 case cohort (n = 48 hospitalized patients from Heidelberg) as well as n = 85 age- and sex-matched pre-pandemic controls from the ESTHER study. Assay validation included comparison with home-made immunofluorescence and commercial enzyme-linked immunosorbent (ELISA) assays. A sensitivity of 100% (95% CI: 86-100%) was achieved in COVID-19 patients 14 days post symptom onset with dual sero-positivity to SARS-CoV-2 N and the receptor-binding domain of the spike protein. The specificity obtained with this algorithm was 100% (95% CI: 96-100%). Antibody responses to ccCoVs N were abundantly high and did not correlate with those to SARS-CoV-2 N. Inclusion of additional SARS-CoV-2 proteins as well as separate assessment of immunoglobulin (Ig) classes M, A, and G allowed for explorative analyses regarding disease progression and course of antibody response. This newly developed SARS-CoV-2 multiplex serology assay achieved high sensitivity and specificity to determine SARS-CoV-2 sero-positivity. Its high throughput ability allows epidemiologic SARS-CoV-2 research in large population-based studies. Inclusion of additional pathogens into the panel as well as separate assessment of Ig isotypes will furthermore allow addressing research questions beyond SARS-CoV-2 sero-prevalence.

Keyword(s): SARS-CoV-2 ; multiplex serology

Note: #EA:F022#LA:F022#

---

Contributing Institute(s):

1. Infektionen und Krebs-Epidemiologie (F022)
2. Infektionen und Krebs-Epidemiologie (F020)
3. D130 B-Zell-Immunologie (D130)
4. D160 Strukturbiologie von Infektion und Immunität (D160)
5. F170 Virus-assoziierte Karzinogenese (F170)
6. C070 Klinische Epidemiologie und Alternf. (C070)

Research Program(s):

1. 316 - Infektionen, Entzündung und Krebs (POF4-316) (POF4-316)

Appears in the scientific report 2021

---

Database coverage:
; ; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF < 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---